NCT01739491View on ClinicalTrials.gov

A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia

WithdrawnOBSERVATIONAL

Timeline

Start Date

October 31, 2014

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

No intervention

This is an obeservational study. Bendamustine hydrochloride will be administered (as per product insert) through intravenous infusion over 30-60 minutes at 100 mg/meter square body surface area on days 1 and 2 of a 28-day cycle.